Fulcrum Therapeutics, Inc. (FULC) closed the last trading session at $11.99, gaining 21.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $19 indicates a 58.5% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $6.89. While the lowest estimate of $7.00 indicates a 41.6% decline from the current price level, the most optimistic a ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) is one of the 12 best multibagger stocks to buy heading into 2026. Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study Following encouraging updates from the ongoing Phase 1b PIONEER study evaluating pociredir in sickle cell disease, analyst sentiment around Fulcrum Therapeutics, Inc. (NASDAQ:FULC) appears to be growing. As of December 18, 2025, 80% of analysts are bullish on Fulcrum Therapeutics, Inc. ( ...

Core Viewpoint - Fulcrum Therapeutics, Inc. has announced a public offering of 11,851,853 shares of common stock priced at $13.50 per share, aiming to raise approximately $175 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering includes pre-funded warrants for certain investors to purchase up to 1,111,193 shares at a price of $13.499 per warrant, reflecting a slight discount from the common stock price [1]. - Fulcrum has granted underwriters a 30-day option to purchase an additional 1,944,456 shares under the same terms [1]. - The offering is expected to close around December 11, 2025, subject to customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily be used for general corporate purposes, including working capital, capital expenditures, and research and development expenses [2]. - Specific allocations may include funding clinical trials, regulatory submissions, commercialization efforts, and potential acquisitions or investments in complementary technologies or assets [2]. Group 3: Company Background - Fulcrum Therapeutics is focused on developing small molecules for patients with genetically defined rare diseases, with its lead program targeting sickle cell disease through the modulation of gene expression [7].

Core Viewpoint - Fulcrum Therapeutics, Inc. has initiated an underwritten public offering of $150 million in common stock, with an option for underwriters to purchase an additional $22.5 million [1][2]. Group 1: Offering Details - The offering is being managed by J.P. Morgan, Leerink Partners, Cantor, Oppenheimer & Co., and Truist Securities [2]. - The shares are being offered under an effective shelf registration statement filed with the SEC on February 27, 2024, and declared effective on April 25, 2024 [3]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available on their website [3][5]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for general corporate purposes, including working capital, capital expenditures, research and development expenses, and potential acquisitions or investments [4]. Group 3: Company Overview - Fulcrum Therapeutics is focused on developing small molecules for patients with genetically defined rare diseases, with its lead program being pociredir for sickle cell disease [7]. - The company utilizes proprietary technology to identify drug targets that can modulate gene expression [7].

Core Viewpoint - Fulcrum Therapeutics Inc. is experiencing a significant stock surge following the release of promising initial results from the 20 mg dose cohort of the Phase 1b PIONEER trial for pociredir in treating sickle cell disease [1][2]. Group 1: Trial Results - The mean absolute fetal hemoglobin (HbF) increased by 9.9% at six weeks of treatment with pociredir, rising from a baseline of 7.1% to 16.9% [3]. - At the data cutoff on November 11, 2025, 58% of patients (7 out of 12) achieved absolute HbF levels of ≥20% at week six, with all patients showing a robust increase in HbF [3][4]. - A clear dose-response was observed, with a >3.75-fold mean induction of HbF at week 12 among patients in the 20 mg cohort, compared to a 2.4-fold mean induction in the 12 mg cohort [5]. Group 2: Safety and Efficacy - The proportion of F-cells (HbF-containing red blood cells) increased from a mean of 31% at baseline to 58% at week six, indicating early progression toward pan-cellular HbF induction [6]. - The safety profile in the 20 mg dose cohort remained consistent with previously reported safety data from the 12 mg cohort [6]. Group 3: Analyst Ratings and Stock Performance - HC Wainwright maintains a Buy rating and raises the price forecast from $18 to $25, while Piper Sandler reiterates an Overweight rating and raises the forecast from $16 to $23 [7]. - Cantor Fitzgerald also maintains an Overweight rating, increasing the price forecast from $15 to $24, and RBC Capital raises its forecast from $7 to $10 while maintaining a Sector Perform rating [7]. - Fulcrum Therapeutics stock is up 9.66% at $14.21 at the time of publication [7].

Market Overview - U.S. stocks experienced a decline, with the Dow Jones index dropping over 200 points, down 0.46% to 47,733.58. The NASDAQ fell 0.32% to 23,501.92, and the S&P 500 also decreased by 0.46% to 6,838.69 [1] - In the commodities market, oil prices fell by 1.6% to $59.14, gold decreased by 0.6% to $4,219.60, silver dropped 1.1% to $58.395, and copper fell 0.7% to $5.4225 [5] Sector Performance - Information technology shares increased by 0.6% on Monday, while communication services stocks saw a decline of 2.1% [1] European Market - European shares showed mixed results, with the eurozone's STOXX 600 falling 0.07%, Spain's IBEX 35 Index rising 0.14%, London's FTSE 100 down 0.23%, Germany's DAX 40 gaining 0.07%, and France's CAC 40 falling 0.08% [6] Asian Market - Asian markets closed mixed, with Japan's Nikkei rising 0.18%, Hong Kong's Hang Seng dipping 1.23%, China's Shanghai Composite increasing by 0.54%, and India's BSE Sensex declining by 0.71% [7] Company News - Structure Therapeutics Inc. saw its shares surge 100% to $68.95 following the announcement of positive topline data from its ACCESS clinical program for aleniglipron, aimed at treating obesity [9] - Wave Life Sciences Ltd. shares increased by 124% to $16.77 after reporting positive interim Phase 1 data for its obesity drug WVE-007 [9] - Fulcrum Therapeutics, Inc. shares rose 63% to $14.50 after initial results from its Phase 1b PIONEER trial of Pociredir in sickle cell disease showed promising outcomes [9] - SMX (Security Matters) Public Limited Company shares dropped 57% to $141.56 after a significant rise of 135% on the previous Friday [9] - BiomX Inc. shares fell 33% to $3.4398 after discontinuing its Phase 2b trial of BX004 in cystic fibrosis patients [9] - Meihua International Medical Technologies Co., Ltd. shares decreased by 38% to $8.66 following the announcement of its delisting from Nasdaq [9]

Market Overview - U.S. stocks experienced a decline, with the Dow Jones index falling over 200 points, down 0.46% to 47,733.58. The NASDAQ decreased by 0.32% to 23,501.92, and the S&P 500 also fell 0.46% to 6,838.69 [1] Sector Performance - Information technology shares increased by 0.6% on the same day, while communication services stocks dropped by 2.1% [1] Commodity Prices - Oil prices fell by 1.6% to $59.14, gold decreased by 0.6% to $4,219.60, silver dropped by 1.1% to $58.395, and copper fell by 0.7% to $5.4225 [5] European Market Performance - European shares showed mixed results, with the eurozone's STOXX 600 down 0.07%, Spain's IBEX 35 Index up 0.14%, London's FTSE 100 down 0.23%, Germany's DAX 40 up 0.07%, and France's CAC 40 down 0.08% [6] Asian Market Performance - Asian markets closed mixed, with Japan's Nikkei rising 0.18%, Hong Kong's Hang Seng down 1.23%, China's Shanghai Composite up 0.54%, and India's BSE Sensex declining 0.71% [7] Company News - Structure Therapeutics Inc. saw its shares surge 100% to $68.95 following positive topline data from its clinical program for obesity treatment [9] - Wave Life Sciences Ltd. shares increased by 124% to $16.77 after reporting positive interim Phase 1 data for its obesity drug [9] - Fulcrum Therapeutics, Inc. shares rose 63% to $14.50 after initial results from its Phase 1b trial showed promising outcomes in sickle cell disease [9] - SMX Public Limited Company shares dropped 57% to $141.56 after a significant rise the previous day [9] - BiomX Inc. shares fell 33% to $3.4398 after discontinuing its Phase 2b trial for cystic fibrosis [9] - Meihua International Medical Technologies Co., Ltd. shares decreased by 38% to $8.66 following the announcement of its delisting from Nasdaq [9]

Group 1 - U.S. stocks experienced a decline, with the Dow Jones falling over 200 points on Monday [1] - Paramount Skydance Corporation launched an all-cash tender offer to acquire Warner Bros. Discovery, Inc. for $30 per share, valuing the company at $108.4 billion [1] - Paramount aims to create a scaled Hollywood leader by merging with Warner Bros. [1] Group 2 - Paramount Skydance shares increased by 9.8% to $14.68 on Monday [2] - Other notable stocks that gained include Wave Life Sciences Ltd., which rose 129.1% to $17.16 after positive interim Phase 1 data for its obesity drug [4] - Structure Therapeutics Inc. saw a gain of 100.5% to $69.30 following the announcement of topline data from its clinical program for obesity treatment [4] Group 3 - Fulcrum Therapeutics, Inc. shares rose 62.3% to $14.44 after reporting initial results from its Phase 1b trial for sickle cell disease [4] - Kymera Therapeutics, Inc. gained 51.2% to $100.75 after reporting successful trial results for its KT-621 drug [4] - Confluent, Inc. shares increased by 29.2% to $29.89 after IBM agreed to acquire the company for $31 per share [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Cemtrex, Inc. (CETX) has increased by 284% to $11.79 - Treasure Global Inc. (TGL) has risen by 135% to $59.83 - Top Wealth Group Holding Limited (TWG) is up 95% at $11.73 - Fulcrum Therapeutics, Inc. (FULC) has gained 49% to $13.29 - MetaVia Inc. (MTVA) is up 33% at $10.90 - Kymera Therapeutics, Inc. (KYMR) has increased by 31% to $87.58 - Confluent, Inc. (CFLT) is up 27% at $29.40 - Immix Biopharma, Inc. (IMMX) has risen by 23% to $6.85 - Nurix Therapeutics, Inc. (NRIX) is up 18% at $21.46 - SU Group Holdings Limited (SUGP) has increased by 15% to $6.44 [3] Premarket Losers - SMX (Security Matters) Public Limited Company (SMX) has decreased by 27% to $242.01 - Meihua International Medical Technologies Co., Ltd. (MHUA) is down 27% at $10.20 - Polyrizon Ltd. (PLRZ) has declined by 16% to $10.90 - Fly-E Group, Inc. (FLYE) is down 16% at $6.90 - Sensei Biotherapeutics, Inc. (SNSE) has decreased by 14% to $8.29 - Kentucky First Federal Bancorp (KFFB) is down 10% at $4.00 - Arteris, Inc. (AIP) has declined by 7% to $16.27 - Fusion Fuel Green PLC (HTOO) is down 6% at $3.89 - Kamada Ltd. (KMDA) has decreased by 5% to $6.69 - iOThree Limited (IOTR) is down 5% at $3.11 [4]

Core Viewpoint - Fulcrum Therapeutics is poised to make significant advancements in the treatment of sickle cell disease, which could greatly improve the lives of patients globally [2]. Company Overview - Alexander Sapir serves as the CEO and President of Fulcrum Therapeutics, leading the company in its mission to develop transformative therapies [1]. - The company is focused on addressing the needs of the sickle cell community, highlighting the potential impact of its drug on patient outcomes [2]. Industry Context - The presentation emphasizes the importance of innovation in the pharmaceutical industry, particularly in the development of treatments for chronic conditions like sickle cell disease [2].